

Corrigendum

**Corrigendum to “Design of novel hexahydropyrazinoquinolines  
as potent and selective dopamine D<sub>3</sub> receptor ligands  
with improved solubility”**

**[Bioorg. Med. Chem. Lett. 16 (2006) 443–446]**

Jianyong Chen,<sup>a</sup> Ke Ding,<sup>a</sup> Beth Levant<sup>b</sup> and Shaomeng Wang<sup>a,\*</sup>

<sup>a</sup>*Departments of Internal Medicine and Medicinal Chemistry, University of Michigan, 1500 East Medical Center Drive,  
Ann Arbor, MI 48109-0934, USA*

<sup>b</sup>*Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City,  
KS 66160-7417, USA*

Available online 22 May 2006

The authors regret that compound **S14297** was mistakenly referred to as **S12947** in Table 1 and as **S12497** in Ref. 18.